In Japan, testing for serum anti-p53 antibodies has been covered by insurance for esophageal cancer, colorectal cancer, and breast cancer since November 1, 2007, based on the higher rate of positivity for serum anti-p53 antibodies compared to other tumor markers even in patients with relatively early-stage cancer. This evidence concerns the gene TP53 and neoplasm.